New Psychiatric Drugs Low Priority for Pharmaceutical Firms, National Institute of Mental Health Reveals

The pharmaceutical industry has largely abandoned drug development for mental illnesses even though depression is a leading cause of disability, experts say. Authors of papers published in this week's issue of the journal Science Translational Medicine argue that drug discovery for treating psychiatric disorders such as autism, schizophrenia, bipolar disorder and depression are at a near standstill.

Back to news